<DOC>
	<DOCNO>NCT00220311</DOCNO>
	<brief_summary>The purpose study confirm efficacy safety fludarabine phosphate administer dose increase 6 cycle ( 1 cycle : 5 treatment day every 28 day ) untreated chronic lymphocytic leukemia ( CLL ) patient anemia and/or thrombocytopenia .</brief_summary>
	<brief_title>A Study Confirm Efficacy Safety Fludarabine Phosphate Administered Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia</brief_title>
	<detailed_description>As 29 May 2009 , clinical trial sponsor Genzyme Corporation . NOTE : This study originally post sponsor Schering AG , Germany , subsequently rename Bayer Schering Pharma AG , Germany .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients histologically cytologically confirm CLL Patients hemoglobin concentration and/or platelet count institution 's low limit normal Patients receive cancer chemotherapy radiotherapy Patients apparent infection ( include viral infection ) Patients serious complication ( heart , liver , kidney disease , etc . ) Patients serious bleed tendency ( e.g. , DIC ) Patients serious CNS symptom Patients fever &gt; = 38Â°C ( exclude tumor fever ) Patients interstitial pneumonia pulmonary fibrosis Patients active multiple cancer Patients receive investigational product within 6 month registration study Patients prior allergy medication similar investigational product ( purine nucleoside derivative ) Women pregnant , childbearing potential , lactate</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>